We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GlaxoSmithKline Initiates Phase III Combo Study on Benlysta
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) initiated a phase III study evaluating human monoclonal antibody — Benlysta (belimumab) — in combination with Roche’s (RHHBY - Free Report) anti-CD20 monoclonal antibody- Rituxan (rituximab) in adult patients with systemic lupus erythematosus (SLE). Benlysta is currently the only medicine specifically developed and approved for SLE.
The study named BLISS-BELIEVE will evaluate the efficacy and safety of Benlysta administered in combination with a single cycle of Rituxan in patients with SLE. The primary endpoint of the study is disease control defined as Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) -2K score <2, that will be achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <5 mg/day at week 52. Clinical remission and durable response with no treatment other than antimalarials, are the secondary endpoints. The study is expected to complete in 2021.
The main aim of the study is to evaluate whether the combination treatment will not only achieve a state of low disease activity, but also achieve clinical remission in patients living with this chronic and unpredictable disease.
Over the year, the shares of the company have declined 13.1% against the industry’s gain of 8.3%.
SLE is a chronic disease and is the most common form of lupus, affecting about 70% percent of an estimated 5 million people with lupus worldwide.
GlaxoSmithKline possesses one of the strongest late-stage pipelines in large-cap pharma. The company is focused on oncology, immuno-inflammation, HIV and respiratory therapeutic areas. The successful development and commercialization of the pipeline candidates should boost the company’s top line.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Ligand’s earnings per share estimates have moved up from $3.78 to $4.20 and from $4.75 to $5.32 for 2018 and 2019, respectively over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 61.2% over a year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
GlaxoSmithKline Initiates Phase III Combo Study on Benlysta
GlaxoSmithKline plc (GSK - Free Report) initiated a phase III study evaluating human monoclonal antibody — Benlysta (belimumab) — in combination with Roche’s (RHHBY - Free Report) anti-CD20 monoclonal antibody- Rituxan (rituximab) in adult patients with systemic lupus erythematosus (SLE). Benlysta is currently the only medicine specifically developed and approved for SLE.
The study named BLISS-BELIEVE will evaluate the efficacy and safety of Benlysta administered in combination with a single cycle of Rituxan in patients with SLE. The primary endpoint of the study is disease control defined as Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) -2K score <2, that will be achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <5 mg/day at week 52. Clinical remission and durable response with no treatment other than antimalarials, are the secondary endpoints. The study is expected to complete in 2021.
The main aim of the study is to evaluate whether the combination treatment will not only achieve a state of low disease activity, but also achieve clinical remission in patients living with this chronic and unpredictable disease.
Over the year, the shares of the company have declined 13.1% against the industry’s gain of 8.3%.
SLE is a chronic disease and is the most common form of lupus, affecting about 70% percent of an estimated 5 million people with lupus worldwide.
GlaxoSmithKline possesses one of the strongest late-stage pipelines in large-cap pharma. The company is focused on oncology, immuno-inflammation, HIV and respiratory therapeutic areas. The successful development and commercialization of the pipeline candidates should boost the company’s top line.
GlaxoSmithKline plc Price
GlaxoSmithKline plc Price | GlaxoSmithKline plc Quote
Zacks Rank & Key Picks
GlaxoSmithKline carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the same space are Regeneron Pharmaceuticals (REGN - Free Report) and Ligand Pharmaceuticals (LGND - Free Report) . Both Regeneron and Ligand sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Ligand’s earnings per share estimates have moved up from $3.78 to $4.20 and from $4.75 to $5.32 for 2018 and 2019, respectively over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 61.2% over a year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>